CanSino's Td5cp Vaccine for Adolescents and Adults Accepted for Registration by NMPA
CanSino Biologics announced that its adsorbed acellular pertussis (five-component) diphtheria-tetanus combined vaccine, abbreviated as Td5cp for adolescents and adults aged six and above, has received an acceptance notice from China's National Medical Products Administration for its drug registration application. The vaccine serves as a booster for pertussis, diphtheria, and tetanus. While such vaccines are routine in developed countries, no similar product is yet approved in China, and successful market entry would fill this domestic gap.
CanSino Biologics Inc. announced that its adsorbed acellular pertussis (five-component) diphtheria-tetanus combined vaccine, intended for individuals aged six years and above and abbreviated as "Td5cp for adolescents and adults," has recently received an "Acceptance Notice" from the National Medical Products Administration (NMPA) for its drug registration application. The vaccine is designed as a booster against pertussis, diphtheria, and tetanus for adolescents and adults.
Currently, major developed countries have incorporated such vaccines into their routine immunization programs, but no adolescent and adult pertussis-diphtheria-tetanus booster vaccine has been approved in China. If the product successfully reaches the market, it will fill a gap in the domestic market.